Welcome to our dedicated page for ELI LILLY & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ELI LILLY & Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ELI LILLY & Co's regulatory disclosures and financial reporting.
Eli Lilly & Co filed an initial ownership report showing a significant equity position in Aktis Oncology, Inc. (AKTS). As of 01/12/2026, Eli Lilly beneficially owned 6,344,114 shares of Aktis Oncology common stock, reported as a direct holding and establishing it as a 10% owner of the company. The filing does not list any derivative securities, so the disclosed stake consists solely of common shares. This type of report is a standard regulatory disclosure of a large shareholder’s position.
Lilly Endowment Inc., a more than 10% owner of Eli Lilly and Company (LLY), reported a series of open-market sales of Eli Lilly common stock on January 7, 2026. The Form 4 shows multiple block sales at weighted average prices generally between $1,085.108 and $1,116.686 per share, with each price reflecting numerous individual trades within narrow ranges as detailed in the footnotes. After these transactions, Lilly Endowment Inc. beneficially owned 91,896,978 shares of Eli Lilly common stock held directly.
Eli Lilly and Company executive Carole Ho, EVP & President of Lilly Neuroscience, reported her beneficial ownership of derivative equity awards. She holds restricted stock units covering 2,741.306 shares of Eli Lilly common stock. These RSUs vest in three installments: 904.631 units on December 1, 2026, 932.044 units on December 1, 2027, and 904.631 units on December 1, 2028. Each restricted stock unit represents a contingent right to receive one share of Eli Lilly common stock, aligning a portion of her compensation with the company’s share performance over time.
Lilly Endowment Inc., a more than 10% owner of Eli Lilly & Co. (LLY), reported a sale of company stock. On 01/05/2026, the reporting person sold 1,390 shares of Eli Lilly common stock at a weighted average price of $1,085.011 per share. The sale was executed in multiple trades at prices ranging from $1,085.00 to $1,085.10.
Following this transaction, the reporting person beneficially owned 92,189,126 shares of Eli Lilly common stock in direct ownership. The filing notes that detailed trade-by-trade pricing information within the reported range will be provided upon request. The form was signed by Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.
Eli Lilly & Co reported an insider transaction by a director-level reporting person. On 12/29/2025, the reporting person sold 3,593 shares of Eli Lilly common stock in an open-market transaction coded "S".
The weighted average sale price was $1,085.035 per share, with individual trades executed between $1,085.00 and $1,085.245. After this sale, the reporting person directly beneficially owned 92,190,516 Eli Lilly shares.
ELI LILLY & Co reported an insider transaction involving its stock. On 12/24/2025, the reporting person sold 2,629 shares of Eli Lilly common stock, listed with transaction code "S". The weighted average sale price was $1,085.173 per share, with individual trades executed between $1,085.00 and $1,085.53.
After this sale, the reporting person beneficially owned 92,194,109 shares of Eli Lilly common stock, held in direct ownership. The footnote explains that detailed trade information within the price range is available upon request from Eli Lilly & Company, its security holders, or the SEC staff.
Lilly Endowment Inc., a director and more than 10% owner of Eli Lilly & Co., reported a small open-market sale of company stock. On 12/23/2025, the reporting person sold 240 shares of common stock, coded as a sale transaction, at a weighted average price of $1,085.038 per share.
The shares were sold in multiple trades at prices ranging from $1,085.00 to $1,085.08. After this transaction, the reporting person beneficially owned 92,196,738 shares of Eli Lilly common stock in direct ownership form. The filer has undertaken to provide detailed trade breakdowns upon request to the company, its security holders, or the SEC staff.
Lilly Endowment Inc. has filed a notice of proposed sale under Rule 144 to sell 300,000 shares of Eli Lilly and Company common stock through Fidelity Capital Markets. The filing reports an aggregate market value of 322,944,000 for these shares, with an approximate sale date of 12/23/2025 and 945,383,757 Eli Lilly shares outstanding.
The notice also lists prior sales of Eli Lilly common stock by Lilly Endowment over the past three months, including 300,000 shares sold on 11/03/2025 for gross proceeds of 266,648,940 and several other large transactions in late September, October, and November 2025. By signing, the seller represents that it is not aware of any material adverse, nonpublic information about Eli Lilly’s operations.
Eli Lilly director Gabrielle Sulzberger reported acquiring 4.668 shares of the company’s common stock on 12/15/2025 at $1,062.19 per share in an insider transaction. Following this transaction, she beneficially owns 2,956.674 shares directly.
The shares were acquired by deferring cash compensation into stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after her separation from service.
Eli Lilly & Co director Juan R. Luciano reported acquiring 13.965 shares of common stock on 12/15/2025 in a transaction coded “A” for acquisition at a price of $1,062.19 per share. After this transaction, he beneficially owned 16,741.37 shares held directly.
The shares acquired have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following Luciano’s separation from service with the company.